COVID-19 | Discovery of “ultra-potent” antibody that blocks multiple variants of the coronavirus

A technology developed at Vanderbilt University Medical Center (United States) has made it possible to discover an “ultra-potent” monoclonal antibody against multiple variants of Sars-CoV-2, the virus responsible for the COVID-19, including delta.

SIGHT: Third dose | “More vaccinated people are needed and no more doses in each person”

The antibody has rare characteristics that make it a valuable addition to the limited pool of widely reactive antibody therapeutic candidates, the researchers explain in a scientific article published in the journal. Cell Reports.

The technology, called LIBRA-seq, has helped accelerate the discovery of antibodies capable of neutralizing SARS-CoV-2. It also allows researchers, but they have a high potential to do so.

SIGHT: COVID-19 vaccine | What are the side effects of the third dose of Pfizer?

In their work, they describe the isolation of a monoclonal antibody from a patient who had recovered from COVID-19 than against Sars-CoV-2. It is also effective against variants of the virus that are holding back efforts to control the pandemic.

The antibody has characteristics genetic rare structural and structural antibodies that distinguish it from other monoclonal antibodies commonly used to treat COVID-19. Sars-CoV-2 is thought to have.

SIGHT: Delta Plus variant of the coronavirus: More contagious and resistant to vaccines?

LIBRA-seq stands for Linking B-cell Receptor to Antigen Specificity through sequencing. Its creators wondered about antibodies and the identities of specific viral antigens, the protein markers that antibodies recognize and attack, simultaneously and with high throughput. The goal was to find a faster way to identify antibodies that target a specific viral antigen.

El Tiempo, Colombia / GDA

• Third dose | “More vaccinated people are needed and no more doses in each person”
• COVID-19 vaccine | What are the side effects of the third dose of Pfizer?
• COVID-19 Treatments: What Works, What Doesn’t, and What’s in Proof
• COVID-19 | Booster shot has similar side effects to the second dose
• COVID-19 causes the biggest drop in life expectancy since World War II
• COVID-19 | Pfizer will request authorization to administer its vaccine to children between 5 and 12 years of age in the United States.
• COVID-19 | Pfizer booster dose increased antibody levels 20 times in Sinovac vaccinated
• Pfizer Starts Human Trials of Messenger RNA Flu Vaccine
• Delta Plus variant of the coronavirus: More contagious and resistant to vaccines?
• COVID-19 | Patients who come to the ICU are mostly men and have more antibodies
• COVID-19 | Results of the Sinopharm clinical trial conducted in Peru will be “very soon”
• Sinopharm will be accepted to travel to the US: reasons to trust the Chinese vaccine
• What are “rogue” antibodies and what do they have to do with severe COVID-19?
• What will the third year of the pandemic be like ?, by Elmer Huerta

Follow us on twitter:

!function(d,s,id){var js,fjs=d.getElementsByTagName(s)[0],p=/^http:/.test(d.location)?’http’:’https’;if(!d.getElementById(id)){js=d.createElement(s);js.id=id;js.src=p+’://platform.twitter.com/widgets.js’;fjs.parentNode.insertBefore(js,fjs);}}(document, ‘script’, ‘twitter-wjs’);

.

Deshawn